IE40930B1 - Decapeptides - Google Patents

Decapeptides

Info

Publication number: IE40930B1
Authority: IE; Ireland
Prior art keywords: leu; arg; tyr; glu; ser
Prior art date: 1973-10-03

Application number

IE2036/74A

Other languages

English (en)

Other versions

IE40930L (en

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1973-10-03

Filing date

1974-10-01

Publication date

1979-09-12

1973-10-03 Priority claimed from US00402958A external-priority patent/US3855199A/en

1973-11-21 Priority claimed from US417983A external-priority patent/US3886137A/en

1974-10-01 Application filed by American Home Prod filed Critical American Home Prod

1975-04-03 Publication of IE40930L publication Critical patent/IE40930L/xx

1979-09-12 Publication of IE40930B1 publication Critical patent/IE40930B1/xx

Links

239000011347 resin Substances 0.000 abstract 6
229920005989 resin Polymers 0.000 abstract 6
108090000765 processed proteins & peptides Proteins 0.000 abstract 4
125000006239 protecting group Chemical group 0.000 abstract 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
231100000252 nontoxic Toxicity 0.000 abstract 3
230000003000 nontoxic effect Effects 0.000 abstract 3
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 3
108010029020 prolylglycine Proteins 0.000 abstract 3
150000003839 salts Chemical class 0.000 abstract 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 abstract 2
238000003776 cleavage reaction Methods 0.000 abstract 2
238000010511 deprotection reaction Methods 0.000 abstract 2
-1 nitro, tosyl Chemical group 0.000 abstract 2
230000007017 scission Effects 0.000 abstract 2
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 abstract 2
IPVYMXZYXFFDGW-UHFFFAOYSA-N 1-methylpiperidin-4-ol;hydrochloride Chemical compound Cl.CN1CCC(O)CC1 IPVYMXZYXFFDGW-UHFFFAOYSA-N 0.000 abstract 1
101100188552 Arabidopsis thaliana OCT3 gene Proteins 0.000 abstract 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 abstract 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
230000001476 alcoholic effect Effects 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
238000005915 ammonolysis reaction Methods 0.000 abstract 1
229940072107 ascorbate Drugs 0.000 abstract 1
235000010323 ascorbic acid Nutrition 0.000 abstract 1
239000011668 ascorbic acid Substances 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
OOCCDEMITAIZTP-UHFFFAOYSA-N cinnamyl alcohol Chemical compound OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
229910000040 hydrogen fluoride Inorganic materials 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
231100000546 inhibition of ovulation Toxicity 0.000 abstract 1
108010055553 leucyl-arginyl-prolyl-glycinamide Proteins 0.000 abstract 1
229940049920 malate Drugs 0.000 abstract 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
108010083476 phenylalanyltryptophan Proteins 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
229910021653 sulphate ion Inorganic materials 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IE2036/74A 1973-10-03 1974-10-01 Decapeptides IE40930B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US00402958A US3855199A (en)	1973-10-03	1973-10-03	P-glu-d-phe-t rp-ser-tyr-d-ala-leu-arg-pro-gly-nh2-and intermediates
US417983A US3886137A (en)	1973-11-21	1973-11-21	P-Glu-D-Phe-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-Gly-NH{HD 2 {B and intermediates

Publications (2)

Publication Number	Publication Date
IE40930L IE40930L (en)	1975-04-03
IE40930B1 true IE40930B1 (en)	1979-09-12

Family

ID=27018102

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE2036/74A IE40930B1 (en)	1973-10-03	1974-10-01	Decapeptides

Country Status (10)

Country	Link
JP (1)	JPS5059367A (fr)
CA (1)	CA1022546A (fr)
CH (1)	CH605676A5 (fr)
DE (1)	DE2447097A1 (fr)
FR (1)	FR2247254B1 (fr)
GB (1)	GB1458685A (fr)
IE (1)	IE40930B1 (fr)
NL (1)	NL7413081A (fr)
NZ (1)	NZ175566A (fr)
PH (1)	PH11571A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4409208A (en) *	1980-04-15	1983-10-11	The Salk Institute For Biological Studies	GnRH antagonists
DE3842010A1 (de) *	1988-12-14	1990-06-21	Hoechst Ag	Kompetitive gonadoliberin-antagonisten

1974
- 1974-09-20 PH PH16314A patent/PH11571A/en unknown
- 1974-09-23 CA CA209,974A patent/CA1022546A/fr not_active Expired
- 1974-09-25 GB GB4161274A patent/GB1458685A/en not_active Expired
- 1974-10-01 IE IE2036/74A patent/IE40930B1/xx unknown
- 1974-10-01 NZ NZ175566A patent/NZ175566A/xx unknown
- 1974-10-02 FR FR7433242A patent/FR2247254B1/fr not_active Expired
- 1974-10-02 CH CH1327474A patent/CH605676A5/xx not_active IP Right Cessation
- 1974-10-02 DE DE19742447097 patent/DE2447097A1/de not_active Withdrawn
- 1974-10-02 JP JP49114274A patent/JPS5059367A/ja active Pending
- 1974-10-03 NL NL7413081A patent/NL7413081A/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
PH11571A (en)	1978-03-31
FR2247254B1 (fr)	1980-01-11
CH605676A5 (fr)	1978-10-13
AU7352074A (en)	1976-03-25
NZ175566A (en)	1978-06-20
FR2247254A1 (fr)	1975-05-09
CA1022546A (fr)	1977-12-13
JPS5059367A (fr)	1975-05-22
NL7413081A (nl)	1975-04-07
GB1458685A (en)	1976-12-15
DE2447097A1 (de)	1975-04-10
IE40930L (en)	1975-04-03

Publication	Publication Date	Title
US4689396A (en)	1987-08-25	GnRH antagonists V
CA1154758A (fr)	1983-10-04	Peptides hydrosolubles ayant une action sur les gonades
EP0100218B1 (fr)	1988-03-30	Antagonistes GnRH
US4253997A (en)	1981-03-03	Anti-ovulatory decapeptides
US4565804A (en)	1986-01-21	GnRH Antagonists VI
CA2029678A1 (fr)	1991-05-14	Isolation et elucidation structurale du dipeptide lineaire cytostatique dolastatine-14
US4569927A (en)	1986-02-11	GnRH Antagonists IV
CA2012480A1 (fr)	1990-11-16	Isolement et elucidation de la structure d'un depsipeptide lineaire cytostatique, le dolastatin 15
AU3132489A (en)	1989-09-21	Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
US5073624A (en)	1991-12-17	Therapeutic decapeptides
US4652550A (en)	1987-03-24	GnRH antagonists VII
EP0162575B1 (fr)	1991-09-04	Antagonistes GNRH VII
GB1535602A (en)	1978-12-13	Lhrh peptide derivatives
EP0063423B1 (fr)	1985-08-14	Antagonistes de GnRH
US4740500A (en)	1988-04-26	GnRH antagonists VIII
IE40930L (en)	1975-04-03	Decapeptides
IE51657B1 (en)	1987-02-04	Lh-rh antagonists
US4377574A (en)	1983-03-22	Contraceptive treatment of male mammals
EP0038135B1 (fr)	1984-07-11	Antagonistes du facteur "LRF"
EP0122712A2 (fr)	1984-10-24	GnRH antagonistes
US4489061A (en)	1984-12-18	Treatment of male mammals
US5618791A (en)	1997-04-08	Memory enhancing peptides
US4386074A (en)	1983-05-31	LRF Antagonists
Erchegi et al.	1981	LH-RH antagonists: further analogs with ring-substituted aromatic residues
IE58287B1 (en)	1993-08-25	Spiro-heteroazolones for treatment of diabetes complications